Program On Regulation, Therapeutics, And Law (PORTAL)
@portalresearch.org
Academic research center at Brigham and Women's Hospital & Harvard Medical School studying the clinical, economic, and legal aspects of medication use.
RETHINKING MEDICATIONS by Jerry Avorn - Out Now! https://rethinkmeds.info/
RETHINKING MEDICATIONS by Jerry Avorn - Out Now! https://rethinkmeds.info/
And, on strategies to improve the biosimilar market, including by implementing policies to facilitate biosimilar interchangeability, clear patent thickets, and preventing biosimilar rebate gaming by PBMs.
April 9, 2025 at 1:57 PM
And, on strategies to improve the biosimilar market, including by implementing policies to facilitate biosimilar interchangeability, clear patent thickets, and preventing biosimilar rebate gaming by PBMs.
On protecting Medicaid - “Cutbacks planned for the Medicaid program will force states to severely limit their drug coverage, which will inevitably lead to patient deaths.”
April 9, 2025 at 1:57 PM
On protecting Medicaid - “Cutbacks planned for the Medicaid program will force states to severely limit their drug coverage, which will inevitably lead to patient deaths.”
WATCH: @akesselheim.bsky.social testifies before @waysmeanscmte.bsky.social
On NIH cuts - "...the next generation will look back at this moment & ask what we were doing while the Trump administration systematically disposed of 1000s of research projects that could've helped patients."
On NIH cuts - "...the next generation will look back at this moment & ask what we were doing while the Trump administration systematically disposed of 1000s of research projects that could've helped patients."
April 9, 2025 at 1:57 PM
WATCH: @akesselheim.bsky.social testifies before @waysmeanscmte.bsky.social
On NIH cuts - "...the next generation will look back at this moment & ask what we were doing while the Trump administration systematically disposed of 1000s of research projects that could've helped patients."
On NIH cuts - "...the next generation will look back at this moment & ask what we were doing while the Trump administration systematically disposed of 1000s of research projects that could've helped patients."
🔎 New in JAMA IM: Avik Ray, @wbfeldman.bsky.social & colleagues assess the comparative effectiveness of diabetes drugs in COPD patients.
They find GLP-1s & SGLT-2s are associated with lower risks of moderate or severe COPD exacerbations vs. DPP-4s during follow-up: jamanetwork.com/journals/jam...
They find GLP-1s & SGLT-2s are associated with lower risks of moderate or severe COPD exacerbations vs. DPP-4s during follow-up: jamanetwork.com/journals/jam...
February 11, 2025 at 4:12 PM
🔎 New in JAMA IM: Avik Ray, @wbfeldman.bsky.social & colleagues assess the comparative effectiveness of diabetes drugs in COPD patients.
They find GLP-1s & SGLT-2s are associated with lower risks of moderate or severe COPD exacerbations vs. DPP-4s during follow-up: jamanetwork.com/journals/jam...
They find GLP-1s & SGLT-2s are associated with lower risks of moderate or severe COPD exacerbations vs. DPP-4s during follow-up: jamanetwork.com/journals/jam...
📣Tune in tomorrow, January 16 at 5pm GMT/12pm ET for a Consilium Scientific webinar led by PORTAL collaborator Ariadna Tibau!
This talk will discuss efforts to identify & prioritize cancer treatments with meaningful clinical benefit & value to patients.
Register here: mailchi.mp/consilium-sc...
This talk will discuss efforts to identify & prioritize cancer treatments with meaningful clinical benefit & value to patients.
Register here: mailchi.mp/consilium-sc...
January 15, 2025 at 3:16 PM
📣Tune in tomorrow, January 16 at 5pm GMT/12pm ET for a Consilium Scientific webinar led by PORTAL collaborator Ariadna Tibau!
This talk will discuss efforts to identify & prioritize cancer treatments with meaningful clinical benefit & value to patients.
Register here: mailchi.mp/consilium-sc...
This talk will discuss efforts to identify & prioritize cancer treatments with meaningful clinical benefit & value to patients.
Register here: mailchi.mp/consilium-sc...
New in JAMA Oncology: Bishal Gyawali & colleagues detail US government contributions to the development of Xtandi, an important (and high-cost) prostate cancer drug.
They find the government contributed at least $74 million to the drug's development: t.co/JbsmP3eFh3
They find the government contributed at least $74 million to the drug's development: t.co/JbsmP3eFh3
December 20, 2024 at 1:34 PM
New in JAMA Oncology: Bishal Gyawali & colleagues detail US government contributions to the development of Xtandi, an important (and high-cost) prostate cancer drug.
They find the government contributed at least $74 million to the drug's development: t.co/JbsmP3eFh3
They find the government contributed at least $74 million to the drug's development: t.co/JbsmP3eFh3
Check out the latest from PORTAL in JHPPL on the lasting effect politics can have on vaccine hesitancy, using the FDA approval and rollout of COVID-19 vaccines in the run-up to the 2020 election as a case study. #publichealth
doi.org/10.1215/03616878-11670184
doi.org/10.1215/03616878-11670184
November 20, 2024 at 7:31 PM
Check out the latest from PORTAL in JHPPL on the lasting effect politics can have on vaccine hesitancy, using the FDA approval and rollout of COVID-19 vaccines in the run-up to the 2020 election as a case study. #publichealth
doi.org/10.1215/03616878-11670184
doi.org/10.1215/03616878-11670184
👋 PORTAL is now on Bluesky! Follow us for the latest research from our team on prescription drug pricing, regulation, law, and policy.
And, to get PORTAL research directly in your inbox each month, subscribe to our newsletter: eepurl.com/iQSXmU
#healthpolicy #rxsky #medsky #lawsky #econsky
And, to get PORTAL research directly in your inbox each month, subscribe to our newsletter: eepurl.com/iQSXmU
#healthpolicy #rxsky #medsky #lawsky #econsky
November 13, 2024 at 4:50 PM
👋 PORTAL is now on Bluesky! Follow us for the latest research from our team on prescription drug pricing, regulation, law, and policy.
And, to get PORTAL research directly in your inbox each month, subscribe to our newsletter: eepurl.com/iQSXmU
#healthpolicy #rxsky #medsky #lawsky #econsky
And, to get PORTAL research directly in your inbox each month, subscribe to our newsletter: eepurl.com/iQSXmU
#healthpolicy #rxsky #medsky #lawsky #econsky